Result of AGM

RNS Number : 1706K

Genedrive PLC

30 December 2020

 

genedrive plc

("genedrive" or the "Company")

Result of AGM

Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

For information, details of the proxy voting are shown below:

	Votes For	Vote For (as % of votes cast)	Votes Against	Votes Against (as % of votes cast)	Votes withheld
1 Receive the Annual report and accounts for the Company	18,105,091	99.6%	76,514	0.4%	98,780
2 Approve the Directors Remuneration Report	18,004,341	99.2%	143,950	0.8%	131,981
3 Re-appoint Tom Lindsay as a director	18,046,634	99.4%	105,545	0.6%	128,206
4 Re-appoint Chris Yates as a director	18,049,104	99.4%	103,075	0.6%	128,206
5 Re-appoint David Budd as a director	18,020,957	99.2%	148,510	0.8%	110,918
6 Re-appoint Matthew Fowler as a director	18,049,104	99.4%	103,075	0.6%	128,206
7 Re-appoint Ian Gilham as a director	16,874,853	99.3%	120,159	0.7%	1,285,373
8 Re-appointment of RSM UK as auditors of the Company	18,062,908	99.6%	79,628	0.4%	137,849
9 Directors authority to allot shares	17,902,887	98.7%	229,670	1.3%	147,828
10 Disapplication of pre-emption rights	16,773,042	92.6%	1,341,787	7.4%	165,041

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website ( www.genedriveplc.com ).

For further details please contact:

genedrive plc	[phone]
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	[phone]
James Steel / Oliver Jackson
finnCap (Joint Broker)	[phone]
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus / Anna Dunphy	[phone] / [phone]

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

 

END

 

 

RAGBDBDDLSXDGGG